A glucagon test (1 mg/m") was performed in healthy subjects (n = ll), obese patients (n = 51, insulindependent diabetics (n = 9), nonobese noninsulin-dependent diabetics (n = 71, and overweight noninsulin-dependent diabetics (n = 8). Previously, they had been connected to the Biostator, modified for continuous blood collection. Endogenous insulin secretion induced by glucagon was derived from integrated C-peptide concentrations.
An index of insulin sensitivity was obtained by dividing the rate of decrease in blood glucose by the total amount of insulin entering the circulation (secreted + infused by the Biostator).
The indices of insulin sensitivity obtained in the above groups of subjects were, respectively, 0.064 2 0.006,0.030 2 0.006, 0.037 2 0.007, 0.021 % 0.006, and 0.016 -C 0.002 mmol/L.U.min (P < 0.001).
The estimated insulin secretion values in the 20 min following glucagon injection were, respectively, 0.38 2 0.05,0.65 2 0.08, 0.05 + 0.01, 0.26 -C 0.15, and 0.30 ? 0.07 LJ (P < 0.001).
The insulin sensitivity index obtained from this test correlated with the glucose MCR obtained from a euglycemic glucose clamp (r = 0.816; P < 0.001; n = 12). C-Peptide levels after glucagon administration were also significantly correlated with the estimated endogenous insulin secretion (r = 0.808; P < 0.001; n = 30). This adaptation of the classical glucagon test is an efficient and simple method to simultaneously evaluate insulin secretion and insulin sensitivity. (J Clin Endocrinol Metab 80: 393-399, 1995) 0 BESITY and noninsulin-dependent diabetes mellitus (NIDDM) are characterized by several abnormalities in insulin secretion and insulin sensitivity (l-3). In the obese subjects, decreased insulin sensitivity is compensated for by an increased insulin secretion. In contrast, in NIDDM patients, insulin secretion is always deficient (4). Nevertheless, this population is highly heterogeneous (5). Insulin resistance is usually evaluated by the euglycemic hyperinsulinemic clamp technique (6). This method has been largely used in type 2 diabetic patients, but is time consuming and does not allow estimation of insulin secretion. Other methods have been proposed; among them is the minimal model applied to a frequently sampled iv glucose tolerance test (7). This method allows evaluation of both pancreatic insulin response and insulin sensitivity (S,). Several groups have reported studies using the minimal model method in diabetic patients. Among these are the original papers describing the insulin-modified method for use in diabetic subjects (8,9), a paper describing the method in insulin-dependent diabetes mellitus (IDDM) (lo), and several subsequent papers in both forms of diabetes (11-13). Nevertheless, this method has not been largely used in NIDDM.
We describe here a modification of the classical glucagon test allowing a quantitative estimate of both insulin secretion and insulin sensitivity.
The test is based on the ability of iv glucagon to stimulate insulin secretion and the efficiency of insulin to decrease the blood glucose levels previously raised by glucagon.
Indices Table 2 . All subjects gave fully informed consent for the study.
They were fasted overnight, and none had taken any 
Instrumentation
The glucose-controlled insulin infusion system used in this study was the Biostator (Miles Martin Laboratories, Eklhart, IN) . This is a closed loop device that continuously samples blood for glucose analysis and infuses insulin to mimic insulin secretion. Before the test, the tube setting of the Biostator was adapted for continuous blood collections, as previously described (15). The operating mode was 3:l. In this mode, insulin infusion is a function of both the actual blood glucose level and the rate of change of blood glucose in the preceding minute, i.r,. more insulin is infused for rising blood glucose levels and less for falling blood glucose levels. The infusion rate constants were: the BI (intended blood glucose) was the blood glucose at the beginning of the test, the RI (insulin infusion rate at the intended "basal" blood glucose) was 0 during the first 20 min of the test and 20 during the last 30 min, the QI (reciprocal for the static gain constant) was 30, the KR (constant for rising blood glucose levels) was 165, and the KF (constant for falling blood glucose levels) was 45. 2) + (F, X b,,,,., x 1 /In 2)1-I, where MCR, is the MCR of C-peptide, V is the distribution volume estimated from the body surface area [BSA; in women, V(L) = 1 .ll X BSA cm*) + 2.04; in men, V(L) = 1.92 X BSA (m") + 0.641, F, is the cleared fraction associated with the short half-life (0.76 for healthy subjects and 0.78 for obese and NIDDM patients), t,,,,,,A is the short half-life (4.95 min for healthy subjects, 4.55 min for obese, and 4.52 min for NIDDM patients), Fz is the cleared fraction associated with the long half-life (1 -F,), and b,S,I'I is the long half-life (in minutes) obtained according to the formula tZ,5,1LX = 0.14 X age (yr) + 29.2. On a molar basis, the amount of C-peptide secreted is identical to the amount of insulin secreted. We considered as an index of B-cell function the insulin secreted during the first 20 min that followed glucagon injection: In this clamp the insulin infusion rate was 100 mU/kg.min for 120 min, and the steady state plasma insulin level was 732 -C 100 pmol/L.
Statistical analysis
The Newman-Keuls-Heartly test was used after a previous analysis of variance.
To compare the tests, a linear regression analysis was performed.
All results are expressed as the mean 2 SEM.
Results
In all subjects studied, the iv injection of 1 mg/m2 glucagon was followed by a rise in blood glucose. This rise was linear with time, at least from lo-20 min (Figs. 1 and 2). Maximum blood glucose levels (9.6 2 0.3 mmol/L) were attained in 16-38 min (mean, 30 2 1 min). No significant differences were seen in the rising blood glucose profile of the different groups of subjects studied. Most subjects exhibited a similar hepatic response to glucagon. However, this response was slightly, but not significantly, higher in IDDM patients.
One IDDM subject showed a peak blood glucose level over 15 mmol/L and was responsible for the wide SD in the blood glucose profile of the IDDM group (Fig. 1) .
In the subsequent decline in blood glucose, both normal controls and IDDM patients showed faster decreases than obese or NIDDM subjects (Fig. 2) . At least from 40-50 min, the decline in blood glucose levels was almost linear with time, as shown by the mean linear regression coefficient (r = -0.974 2 0.005). During that time, the rates of decrease in blood glucose concentration were significantly (P < 0. In an obese nondiabetic patient, exogenous insulin was not infused during the second part of the test; in this patient, the blood glucose level kept rising for more than 80 min after glucagon injection (basally and 20,40,60, and 80 min after glucagon, blood glucose levels were, respectively, 4.5, 7.4, 8.7, 9.2, and 9.3 mmol/L). This patient was not included in the statistical analysis or in the figures.
Compared to normal controls, the obese subjects showed a significantly greater endogenous insulin secretion (Table  3) . In all IDDM patients, the endogenous insulin secretion was extremely low. By contrast, NIDDM patients showed an important heterogeneity in terms of endogenous insulin response to glucagon.
In the nonobese NIDDM group, the endogenous insulin secretion tended to be slightly lower than that in lean controls or overweight NIDDM patients (Table 3) . Thanks to the connection to the Biostator, a deficient endogenous insulin secretion was compensated for by a higher exogenous insulin infusion in the second part of the test (Table 3) .
The index of sensitivity to insulin, calculated by dividing the rate of decrease in blood glucose in the last 10 min of the test by the total amount of insulin entering the circulation, is lower in obese subjects and even more decreased in NIDDM patients than in normal controls and IDDM patients (Table  4 ). This last group of patients had an index of insulin sensitivity slightly lower than normal (0.037 ? 0.007 ZIS. 0.064 5 0.006 mmol/L.U.min; P < 0.05). Insulin sensitivity was slightly, but not significantly, lower in obese than in nonobese NIDDM patients (Table 4 ). The calculated values for endogenously secreted insulin in our test were significantly correlated to both basal and stimulated (6 and 15 min after glucagon treatment) plasma Cpeptide levels. The regression coefficient between EIS and the area under the curve of C-peptide levels postglucagon was r = 0.808; P < 0.001 (Fig. 3) . In 12 randomly selected subjects, we also compared the above-described index of insulin sensitivity with other indices of insulin sensitivity obtained from a 2-h euglycemic hyperinsulinemic clamp. A good correlation (r = 0.816; P < 0.001) was obtained between the IS1 and the MCR of glucose (Fig. 3) . Finally, the reproducibility of the test was investigated in 6 healthy volunteers who underwent 3 tests, several weeks apart. The withinsubject coefficient of variation was 19.0 + 4.7% for the IS1 index and 23.3 2 5.4% for EIS.
Discussion
The glucagon test is a classical means of evaluating endogenous insulin secretion (14) . In this paper, we present an adaptation of this test which, in addition, gives some information on insulin sensitivity.
The estimate of insulin sensitivity was obtained by comparing the decline in blood glucose levels and the total amount of insulin entering the circulation.
As insulin secretion is markedly deficient in some diabetic patients, we used a glucose-controlled insulin infusion in the last 30 min of the test to induce a rapid decrease in blood glucose levels. In our calculations, we included the total amount of insulin secreted plus infused during the whole test. By contrast, we only considered the rate of decrease in blood glucose during the last 10 min (from 50 to 40 min). The justification of this approach is: 1) at that time, the rate of decrease in blood glucose is linear with time; 2) the blood glucose decrease is mostly dependent upon insulin because at that time, the injected glucagon has almost disappeared from the circulation (22); and 3) it is well known that the insulin-induced glucose uptake is dependent, not on the actual insulin concentration in the plasma compartment, but in the so-called remote active compartment (7). It has been reported that blood glucose correlated better with the concentration of insulin in interstitial fluid than to the plasma insulin levels, and that the insulin peak in the interstitial fluid was recorded 50-60 min later than in the plasma (23).
Our hepatic glucose production and the insulin-induced glucose disposal (as well as, to some extent, the insulin-independent glucose disposal). The decrease in hepatic glucose production may be determined by both insulin action and the waning effect of time over glucagon-induced hepatic glucose production.
Nevertheless, in our study conditions the first mechanism seems more operative. When the glucagon test was performed without infusing insulin, the blood glucose levels remained elevated for at least the next 80 min.
The rate of increase in blood glucose levels after glucagon injection has been classically considered as a reliable index of the hepatic ability to increase glucose output (28). In the various populations studied, the blood glucose response to glucagon was very similar. Only in diabetic patients, both IDDM and NIDDM, was the blood glucose peak delayed. This is probably due to the diminished endogenous insulin secretion.
Recently, it has been reported that it is possible to estimate insulin secretion rates from plasma C-peptide levels using standard parameters for C-peptide clearance rather than individually derived parameters (19). This approach does not determine a significant loss of accuracy compared to the administration of exogenous C-peptide to characterize Cpeptide kinetics and enable valid calculation of insulin secretion, at least for chosen groups of subjects. The advantages of C-peptide as a marker of insulin secretion have also been recently pointed out (29). The estimated insulin secretion is significantly correlated to the area under the curve of Cpeptide levels, although this correlation requires all of the different subject groups to be included, even those with low insulin secretion, such as IDDM and nonobese NIDDM patients.
As expected, the endogenous insulin secretion was increased in obese subjects. By contrast, it was almost negligible in IDDM patients; this is a common finding after 10 yr of the disease. In NIDDM patients, a deficient insulin secretion was also observed. However, there was a high between-subject heterogeneity, even after separating moderately obese and nonobese patients. This finding confirms previous data (30, 31). Different etiologies may exist for NIDDM in obese and nonobese subjects (32), but even within a homogenous NIDDM population, at least two subgroups of subjects may exist: one with primary insulin deficiency and normal insulin action, and the other with very mild impairment in insulin secretion but primary peripheral insulin resistance (33). The rate of decrease in blood glucose was significantly different among the different groups of subjects studied. In obese subjects, it was small despite both a high endogenous secretion and a high infusion of exogenous insulin. Therefore, a low index of sensitivity to insulin has been obtained. This is in accordance with the well documented insulin resistance of obesity (3,34). The decrease in insulin sensitivity observed here is similar to that characterized by the glucose clamp (35, 36) or the glucose and insulin infusion test (36). As recently reported, some methods may have difficulties in determining differences in insulin sensitivity in obese and normal subjects (36).
In IDDM patients, comparison of the amount of insulin infused and the rate of decrease in blood glucose gives an index of insulin sensitivity slightly lower than that in normal controls. This is in agreement with other studies (10,37-39), and it may also partly reflect the different ways insulin enters the circulation (peripheral us. portal). A recent report has shown that, at least in IDDM subjects, the minimal model may overestimate the effect of glucose and underestimate the effect of insulin on net glucose disappearance (13). In any case, the IS1 was markedly and significantly higher in IDDM than in NIDDM patients. In most of the NIDDM patients, the insulin efficiency to decrease blood glucose was very low, lower than that observed in obese nondiabetic patients. Our results agree with other observations showing severe insulin resistance in NIDDM (3, 4, 40) and the hypothesis of a relative contribution of both insulin deficiency and insulin resistance in type 2 diabetes mellitus (4, 30 
